Antigenics' cancer drug shows early survival edge (Reuters)


Reuters - Antigenics Inc. said on Monday a
preliminary analysis showed certain advanced skin cancer
patients taking its Oncophage vaccine survived more than 50
percent longer in a late-stage test, sending shares up 30
percent in pre-market trading.